Sunshine Biopharma Reports 2023 First Quarter Results: Revenues Up 2,100%
MONTREAL, May 11, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines...
COVID-19
Vir Biotechnology Announces First Patient Dosed in New Phase 2 Chronic Hepatitis B Virus Trial Evaluating Combinations of VIR-2218, VIR-3434, PEG-IFNα and an NRTI
– STRIVE is the first Phase 2 sub-protocol trial initiated under Vir’s new PREVAIL platform trial investigating the Company’s novel...
Comera Life Sciences Reports Financial Results for First Quarter 2023 and Recent Business Highlights
– Significant progress in Comera’s ongoing research collaboration with Regeneron, a leading U.S. biotechnology company – – Further development of...
Oncocyte Reports First Quarter 2023 Financial Results
Nearing Manufacturing Start Up of First Kitted ProductIRVINE, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision...
RAPT Therapeutics Reports First Quarter 2023 Financial Results
Company maintains strong cash position of $231.6 millionSOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc....
IMUNON Reports First Quarter 2023 Financial Results and Provides Business Update
Non-Viral DNA-Mediated Immunotherapy and Next-Generation Vaccine Programs with Multiple Near-Term Milestones Supported by a Strong Balance Sheet Conference Call Begins...
ReWalk Robotics Reports First Quarter 2023 Financial Results
On-Track Start to Fiscal Year with Progress in Advancing Reimbursement Coverage for Medicare Beneficiaries MARLBOROUGH, Mass. BERLIN and YOKNEAM ILLIT, Israel,...
Daré Bioscience Reports First Quarter 2023 Financial Results and Provides a Company Update
Conference Call and Webcast Today at 4:30 p.m. ET 2023 Anticipated Milestones: Sildenafil Cream, 3.6% for Female Sexual Arousal Disorder...
New Long-Term Real-World Research Confirms Xoft Skin eBx is as Safe and Effective as Mohs Surgery
98.9% of patients treated with Xoft remained recurrence-free at a median follow-up of 7.6 years, according to recent study published...
NeuroOne® Announces First Clinical Case Using Evo® sEEG Electrode Performed at Mayo Clinic
Evo sEEG electrodes used for brain mapping in epilepsy surgery EDEN PRAIRIE, Minn., May 10, 2023 (GLOBE NEWSWIRE) -- NeuroOne...
Bioventus Announces Divestiture of its Wound Business
DURHAM, N.C., May 10, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations...
Medhealth Outlook Selects TOMI Environmental Solutions as One of the Top 10 Infection Control Solution Providers of 2023
FREDERICK, Md., May 10, 2023 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in...
Dyadic to Participate at Two Industry Events in May
JUPITER, Fla., May 10, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology...
Alpha Pro Tech, Ltd. Announces First Quarter 2023 Financial Results
Disposable Protective Garment Sales Increased by 10.6% to $4.4 Million Compared to the Prior Year PeriodNet sales for the first...
Amgen and TScan Therapeutics Announce Collaboration to Identify Novel Targets in Crohn’s Disease
Collaboration Brings Together TScan’s Proprietary Target Discovery Platform and Amgen’s Inflammation Therapeutic Expertise and Research Capabilities TScan to Receive $30...
AIM ImmunoTech to Discuss First Quarter 2023 Financial Results on May 16, 2023 and Host Conference Call and Webcast
OCALA, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company...
SeqLL Provides First Quarter 2023 Financial Results
BILLERICA, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL; SQLLW), a technology company...
SAB Biotherapeutics Announces Progress on U.S. FDA’s Phased Review of Company’s Groundbreaking DiversitAb™ Platform
- FDA has approved five of seven sections in a rolling submission required for a New Animal Drug Application (NADA)...
Vaxxinity Reports First Quarter 2023 Financial Results and Provides Corporate Update
Vaxxinity corporate headquarters in Cape Canaveral, Fla. Vaxxinity corporate headquarters in Cape Canaveral, Fla. (Photo: Vaxxinity)CAPE CANAVERAL, Fla., May 09,...
Madrigal Pharmaceuticals Provides Corporate Updates and Reports First Quarter 2023 Financial Results
Resmetirom new drug application (NDA) filing on track for Q2 2023Resmetirom has received Breakthrough Therapy designation from FDA Multiple resmetirom...